Description:
Lornoxicam is a non steroidal anti-inflammatory and analgesic drug, a thiazide derivative with strong antipyretic, analgesic, and anti-inflammatory effects. It relatively inhibits the activity of two isomers of cyclooxygenase (COX) in a balanced manner, thereby inhibiting the biosynthesis of prostaglandins and producing anti-inflammatory and analgesic effects. The COX1: COX2 inhibition rate of this drug is 0.6, therefore it has the good analgesic effect of traditional NSAID. At the same time, the drug does not inhibit the activity of 5-lipoxygenase, so it does not inhibit the synthesis of leukotriene, nor does it shunt arachidonic acid to the 5-lipoxygenase pathway, while arachidonic acid and the metabolites of 5-lipoxygenase can inhibit the impulse process of nociceptors in the spinal cord, thus allowing lornoxicam to exert the analgesic effect similar to that of opioid peptide analgesics. Both lornoxicam and naproxen can significantly reduce the rest pain score, joint tenderness index, and joint swelling index of OA patients. There is no significant difference between the two drugs, but lornoxicam has a better effect on improving the activity pain score of patients than naproxen. Animal in vivo safety studies have shown that the toxicity characteristics are consistent with the inhibitory effect of half oxidase. The digestive tract and kidneys are the most sensitive organs to toxic effects. The results of animal experiments indicate that lornoxicam for injection has no vascular or muscle irritation, and does not cause allergies or hemolysis.
Function:
Non steroidal anti-inflammatory and analgesic drugs. Inhibition of prostaglandin synthesis by blocking cyclooxygenase, but has no effect on ester oxygenase.
It can be used for acute pain, acute sciatica, or low back pain after gynecological and orthopedic surgeries. It can also be used for chronic low back pain, arthritis, rheumatoid arthritis, and ankylosing spondylitis.
Mechanism of Action:
Lornoxicam is a nonsteroidal anti-inflammatory and analgesic drug. It is a derivative of thiazide and has strong anti-inflammatory and analgesic effects. Its mechanism of action includes: 1. inhibiting prostaglandin synthesis by inhibiting the activity of cyclooxygenase (COX). Chemicalbook However, Lornoxicam does not inhibit the activity of 5-lipoxygenase, so it does not inhibit the synthesis of leukotriene, nor does it shunt arachidonic acid to 5-lipoxygenase. 2. Activate the opioid neuropeptide system and exert central analgesic effects.
Hebei Jingbo New Material Technology Co., Ltd. was founded in 2007 , located in Shijiazhuang city which is the capital of Hebei Province and hub sector among Beijing Tianjin and Hebei and has advantage of convenient transportation . Our company is a modern high-tech chemical enterprise with Research & Development, production and sales.Our company has strong technical strength, advanced equipment, strict quality management system and high-quality after-sales service, adhers to the "customer first and forge ahead" business philosophy and insists on integrity as the company's survival.
China
